8-K: Lyell Immunopharma Q4/FY25: Pipeline Advances, Cash Runway

Lyell Immunopharma reported Q4 and full year 2025 financial results, highlighting significant clinical progress in its CAR T-cell therapy pipeline and an extended cash runway.

Summary

• Patient dosing has commenced in the first-of-its-kind Phase 3 head-to-head CAR T-cell randomized controlled clinical trial (PiNACLE-H2H) for ronde-cel in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) setting.
• The pivotal PiNACLE trial evaluating ronde-cel in patients with R/R LBCL in the thirdor later-line (3L+) setting is ongoing, with pivotal data supporting BLA submission expected mid-2027.
• The Phase 1 trial for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer (mCRC), is ongoing, with seven new patients treated without dose-limiting toxicity and dose escalation to Dose Level 3.
• Smital Shah was appointed Chief Financial and Business Officer in March 2026.
• The second $50 million tranche of a $100 million equity private placement closed in March 2026, following the achievement of a clinical milestone for ronde-cel.
• Cash, cash equivalents, and marketable securities were approximately $247.2 million as of December 31, 2025, excluding the $50 million tranche received in March 2026.
• Current cash is expected to advance the pipeline into the second quarter of 2027, including through multiple key clinical milestones.
• Net loss for the fourth quarter and full year ended December 31, 2025, was $140.7 million and $274.4 million, respectively, compared to $191.9 million and $343.0 million for the same periods in 2024.
• Non-GAAP net loss for the fourth quarter and full year ended December 31, 2025, was $33.1 million and $144.8 million, respectively, compared to $45.9 million and $159.5 million for the same periods in 2024.
• Ronde-cel demonstrated a 93% best overall response rate and a 76% complete response rate in 29 efficacy-evaluable 3L+ LBCL patients, with a median progression-free survival of 18 months.
• Ronde-cel also showed an 83% best overall response rate and a 61% complete response rate in 18 efficacy-evaluable 2L LBCL patients (94% with high-risk primary refractory disease).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by significant clinical advancements in two key programs, improved financial metrics (reduced losses), and an extended cash runway, all of which de-risk the company's near-term operational outlook.

Positives

• Commencement of patient dosing in the Phase 3 PiNACLE-H2H trial for ronde-cel, marking a significant advancement into late-stage clinical development.
• The pivotal PiNACLE trial for ronde-cel is ongoing, with BLA submission data expected in mid-2027, indicating a clear path towards potential regulatory approval.
• Encouraging emerging safety profile and clinical activity observed with LYL273 in metastatic colorectal cancer, including dose escalation to Dose Level 3 without dose-limiting toxicity.
• Successful closing of the second $50 million tranche of the $100 million equity private placement, demonstrating continued investor confidence tied to a clinical milestone.
• Extended cash runway into the second quarter of 2027, providing financial stability to achieve multiple key clinical milestones.
• Reduced GAAP net loss for Q4 2025 ($140.7 million vs. $191.9 million in Q4 2024) and full year 2025 ($274.4 million vs. $343.0 million in FY 2024).
• Reduced Non-GAAP net loss for Q4 2025 ($33.1 million vs. $45.9 million in Q4 2024) and full year 2025 ($144.8 million vs. $159.5 million in FY 2024).
• Strong clinical data for ronde-cel: 93% overall response rate and 76% complete response rate in 3L+ LBCL, with a median progression-free survival of 18 months.
• Ronde-cel's safety profile was appropriate for outpatient administration, with no Grade 3 cytokine release syndrome and a 4% rate of Grade 3 immune cell-associated neurotoxicity syndrome with dexamethasone prophylaxis.
• LYL273 showed a 67% best overall response rate, an 83% disease control rate, and an 8-month median progression-free survival at the highest dose level tested (Dose Level 2) in refractory mCRC patients.
• Ronde-cel received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for R/R LBCL.
• LYL273 received Fast Track designation from the FDA for mCRC.

Negatives

• Continued net losses, with a GAAP net loss of $274.4 million for the full year 2025.
• Research and development (R&D) expenses increased in Q4 2025 to $52.2 million from $48.7 million in Q4 2024, primarily due to a $19.7 million stock-based compensation expense related to the LYL273 license acquisition.

Risks

• Limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials.
• The nonclinical profiles of product candidates or technology may not translate into clinical trials.
• Potential for results from clinical trials to differ from nonclinical, early clinical, preliminary, or expected results.
• Significant adverse events, toxicities, or other undesirable side effects associated with product candidates.
• Ability to make planned regulatory submissions or progress clinical trials on anticipated timelines, if at all.
• RMAT and Fast Track designations may not actually lead to faster development, regulatory review, or approval process, and do not assure ultimate FDA approval.
• Significant uncertainty associated with product candidates ever receiving any regulatory approvals.
• Ability to obtain, maintain, or protect intellectual property rights related to product candidates.
• Complexity of manufacturing cellular therapies and ability to manufacture and supply product candidates for clinical trials.
• Implementation of strategic plans for the business and product candidates and realization of the expected benefits of such plans.
• Potential reduction of cash resources and fluctuations in operating results and financial condition as a result of milestone, royalty, and success payment obligations.
• Sufficiency of capital resources and need for additional capital to achieve goals.

Future Outlook

Lyell expects to achieve multiple clinical milestones in the next 12 to 18 months. Pivotal data from the PiNACLE trial supporting a Biologics License Application (BLA) submission to the FDA is anticipated in mid-2027. The company believes its current cash, cash equivalents, and marketable securities will be sufficient to meet working capital and capital expenditure needs into the second quarter of 2027, including through these key clinical milestones.

Management Comments

• "We have now advanced ronde-cel into two pivotal clinical trials, with the pivotal data supporting BLA submission from the PiNACLE trial expected to be reported mid-next year."
• "With the encouraging emerging safety profile and clinical activity observed with LYL273 in patients with metastatic colorectal cancer, we believe Lyell is well-positioned with two next-generation CAR T-cell product candidates."

Industry Context

StockSavvy.ai notes that Lyell Immunopharma's progress in CAR T-cell therapies, particularly with dual-targeting and enhanced stem-like features, positions it within a highly competitive and rapidly evolving oncology landscape. The initiation of a Phase 3 head-to-head trial (PiNACLE-H2H) against established CD19-targeted CAR T-cell therapies like axi-cel and liso-cel is a bold move, indicating confidence in ronde-cel's potential to offer superior outcomes in large B-cell lymphoma. The development of LYL273 for metastatic colorectal cancer addresses a significant unmet need in solid tumors, a notoriously challenging area for CAR T-cell efficacy.

Comparison to Industry Standards

• Ronde-cel's reported 76% complete response rate in 3L+ LBCL and 61% in 2L LBCL (high-risk primary refractory) compares favorably to historical data for approved single-target CD19 CAR T-cells, which typically show CR rates in the 40-50% range for similar patient populations in pivotal trials (e.g., Yescarta (axi-cel) in ZUMA-1, Kymriah (tisa-cel) in JULIET). The median PFS of 18 months for 3L+ LBCL is also a strong indicator of durability.
• The 67% overall response rate and 8-month median progression-free survival for LYL273 in refractory metastatic colorectal cancer are notable, as CAR T-cell therapies have historically struggled to achieve significant responses in solid tumors due to the hostile tumor microenvironment and antigen heterogeneity. This early data suggests LYL273's enhancements may be overcoming some of these challenges, potentially outperforming conventional chemotherapy or targeted therapies in this heavily pre-treated population.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, extended cash runway, and reduced losses, potentially increasing investor confidence and future valuation.
• Patients: Potential for new, more effective CAR T-cell therapies for large B-cell lymphoma and metastatic colorectal cancer, addressing unmet medical needs.
• Employees: Stable outlook with continued clinical development and strategic appointments, though prior workforce reduction was noted.
• Creditors: Improved financial stability and an extended cash runway reduce immediate concerns regarding liquidity.

Next Steps

• Continue enrollment and patient dosing in the pivotal PiNACLE trial for ronde-cel.
• Continue enrollment and patient dosing in the Phase 3 PiNACLE-H2H trial for ronde-cel.
• Continue enrollment in the U.S. Phase 1 clinical trial for LYL273 to determine the recommended Phase 2 dose.
• Report pivotal data from the PiNACLE trial in mid-2027 to support BLA submission.
• Achieve multiple clinical milestones in the next 12 to 18 months.

Key Dates

Recommendation

The filing demonstrates significant clinical momentum with two CAR T-cell candidates, particularly the initiation of a Phase 3 head-to-head trial for ronde-cel and promising early data for LYL273 in solid tumors. Reduced net losses and an extended cash runway into Q2 2027 provide a solid financial foundation for these advancements. The achievement of a clinical milestone triggering a $50 million equity tranche further validates progress. These factors collectively suggest a strong upside potential for the stock, warranting a "strong buy" recommendation for seasoned investors.

Keywords

Lyell Immunopharma, LYEL, CAR T-cell therapy, oncology, large B-cell lymphoma, colorectal cancer, ronde-cel, LYL273, PiNACLE, PiNACLE-H2H, financial results, clinical trials, biotechnology, pharmaceuticals, RMAT, Fast Track